Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

VerifiedinfoResponsive

Provita Centrum Medyczne Sp. z o.o.

Poland Ul. Jana Pawla II 35, 97-200 Tomaszow Mazowiecki, Poland

  • 12 trials recruiting
  • Non-small cell lung cancer · Prostate cancer metastatic · Squamous cell carcinoma of lung
  • Adult patients

About Specializations

Provita Centrum Medyczne Sp. z o.o. in Tomaszow Mazowiecki, Poland specialises in clinical trials of conditions such as Non-small cell lung cancer, Prostate cancer metastatic, Squamous cell carcinoma of lung, Non-small cell lung cancer stage IV, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms – Oncology Research

Provita Centrum Medyczne is conducting focused oncology trials aimed at improving outcomes for patients with advanced cancers. The studies evaluate novel pembrolizumab and nivolumab based immunotherapy combinations, as well as enzalutamide strategies, to extend overall survival and delay disease progression in metastatic castration‑resistant prostate cancer and non‑small cell lung cancer.

  • Metastatic castration‑resistant prostate cancer
  • Previously untreated locally advanced non‑small cell lung cancer
  • Combination of checkpoint inhibitors with androgen receptor blockade
  • Assessment of progression‑free and overall survival

The eight investigators at this hospital‑clinic collaborate to bring cutting‑edge cancer research to Tomaszów Mazowiecki, Poland.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Jana Pawla II 3597-200 Tomaszow MazowieckiPoland
Open in maps ↗
Recruiting now
12 trials
Conditions studied
27
Partner status
Verified

More sites in Tomaszow MazowieckiPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

22 clinical trials

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting
Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Smoking cessation therapy+1

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cytisine
  • Sponsor:University of Rzeszow

Squamous cell carcinoma of lung+4

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Prostate cancer metastatic

Recruiting
InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD0516
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of lung+8

Recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Non-small cell lung cancer

Recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer

Recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Pfizer Inc.

Clear cell renal cell carcinoma

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AB521
  • Sponsor:Arcus Biosciences Inc.

Non-small cell lung cancer+1

Recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study on the Effects and Safety of Finerenone for Patients with Heart Failure Who Cannot Use Steroidal Mineralocorticoid Receptor Antagonists

Recruiting
Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Hormone-refractory prostate cancer+1

Recruiting
Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Small cell lung cancer

Recruiting
Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.